SciSparc Ltd. (NASDAQ:SPRC) Short Interest Down 56.3% in October

SciSparc Ltd. (NASDAQ:SPRC) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 363,100 shares, a decline of 56.3% from the September 30th total of 831,500 shares. Based on an average daily trading volume, of 3,020,000 shares, the short-interest ratio is presently 0.1 days. Approximately 3.5% of the shares of the stock are short sold.

SciSparc Stock Performance

Shares of SciSparc stock remained flat at $0.23 on Friday. 423,344 shares of the stock traded hands, compared to its average volume of 1,679,308. SciSparc has a 12-month low of $0.21 and a 12-month high of $14.22. The company’s 50-day simple moving average is $0.29 and its 200-day simple moving average is $0.71.

Institutional Investors Weigh In On SciSparc

An institutional investor recently bought a new position in SciSparc stock. Renaissance Technologies LLC acquired a new position in SciSparc Ltd. (NASDAQ:SPRC) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc at the end of the most recent quarter. 25.06% of the stock is owned by hedge funds and other institutional investors.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.